quetiapine extended-release / Generic mfg. - LARVOL DELTA

Acute catatonia and psychosis in the context of seizure exacerbation in epilepsy: a case report. (PubMed, Front Psychiatry) - "We report a 44-year-old woman with a 27-year history of epilepsy, maintained on carbamazepine and topiramate, and a longstanding psychiatric history of major depressive disorder, obsessive-compulsive symptoms, and chronic nihilistic delusions and intermittent hallucinations documented at baseline. One week before admission, her antidepressant was switched from clomipramine to venlafaxine 150 mg/day...Management with escalating benzodiazepines and cautious antipsychotic uptitration (quetiapine XR, cariprazine) was associated with complete catatonic remission and psychotic symptom resolution over 29 days...Clinicians should resist anchoring on temporal associations between seizure activity and psychiatric symptoms. EEG findings must be interpreted in their pharmacological context; pharmacokinetic interactions should inform antipsychotic dose selection; and QTc prolongation warrants structured cardiac monitoring."

Journal • Anesthesia • CNS Disorders • Depression • Epilepsy • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • CYP3A4

C-SAPP: Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (clinicaltrials.gov) - P4 | N=358 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Aug 2027 ➔ Aug 2028 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Study of rTMS in Maintenance in Treatment Resistant Depression (clinicaltrials.gov) - P3 | N=68 | Not yet recruiting | Sponsor: All India Institute of Medical Sciences, Bhubaneswar

New P3 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence. (PubMed, CNS Drugs) - "Reviewed treatments included atypical antipsychotics (aripiprazole, brexpiprazole, olanzapine, quetiapine XR, risperidone, cariprazine), bupropion, ketamine/esketamine, lithium, mirtazapine/mianserin, modafinil, and triiodothyronine...Aripiprazole, brexpiprazole, quetiapine XR, and ketamine/esketamine have been shown to improve depression and/or anxiety symptoms in patients with MDD with anxiety symptoms, although evidence is mainly short-term and derived from exploratory post hoc analyses of trials not designed to assess anxiety outcomes. Treatment decisions for patients with MDD with anxiety symptoms should be based on robust clinical data, and there is an unmet need for prospective clinical trials with anxiety-specific endpoints in this patient population."

Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Comparative Augmentative Efficacy of Second-Generation Antipsychotics in Adult Treatment-Resistant Depression: A Systematic Review. (PubMed, Cureus) - "Eleven randomized controlled trials including 5,300 participants were analyzed, evaluating brexpiprazole, cariprazine, aripiprazole, and quetiapine XR. Careful risk-benefit assessment and monitoring for adverse effects are essential. Further head-to-head and long-term studies are needed to guide personalized treatment."

Journal • Review • CNS Disorders • Depression • Insomnia • Major Depressive Disorder • Mood Disorders • Psychiatry • Sleep Disorder

Efficacy, acceptability, and related outcomes of pharmacological interventions for acute bipolar depression: A systematic review and dose-related network meta-analysis across different age groups. (PubMed, J Affect Disord) - "Our findings are consistent with previous NMAs and current guidelines, thereby expanding knowledge by concurrently appraising different drugs, doses, and age groups."

Journal • Retrospective data • Review • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Pediatrics • Psychiatry

Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis. (PubMed, Adv Ther) - "Lumateperone represents an effective adjunctive therapy for adult MDD, with no weight change."

Clinical • Journal • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

COMPARATIVE EFFICACY AND SAFETY OF LUMATEPERONE AND OTHER ATYPICAL ANTIPSYCHOTICS APPROVED AS ADJUNCTIVE THERAPY FOR MAJOR DEPRESSIVE DISORDER: A NETWORK META-ANALYSIS (ISPOR 2026) - "This network meta-analysis (NMA) compared efficacy and safety of lumateperone with other approved atypical antipsychotics: aripiprazole, brexpiprazole, cariprazine, and quetiapine XR for MDD with inadequate response to antidepressants (ADT). Ten short-term, randomized, double-blind, placebo-controlled registration trials formed a star-shaped network of 11 treatment- and dose-specific nodes anchored on placebo+ADT. In this NMA, lumateperone demonstrated a favorable efficacy profile versus other approved adjunctive antipsychotics, with no increased risk of weight gain. Balancing efficacy and safety is crucial when selecting adjunctive antipsychotic treatment for MDD."

Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (PubMed, JAMA Psychiatry) - "A total of 22 short-term studies comprising 10 962 participants (aripiprazole: n = 1297; brexpiprazole: n = 1973; cariprazine: n = 1894; lumateperone: n = 483; quetiapine extended release [XR]: n = 719; and placebo: n = 4596) were included for analysis. This systematic review and meta-analysis indicates that differences exist between adjunctive atypical antipsychotics in the treatment of MDD with respect to overall efficacy and acceptability, which should be simultaneously considered. The absence of adequate and well-controlled studies documenting maintenance efficacy of adjunctive atypical antipsychotics in MDD remains a knowledge gap."

Journal • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study. (PubMed, Int J Neuropsychopharmacol) - P2 | "Results support the favorable tolerability and preliminary efficacy of seltorexant 20 mg daily as adjunctive treatment in patients with MDD, especially those with insomnia symptoms, and suggest potential approaches to differentiate seltorexant from quetiapine-XR in future adequately powered studies. Trial registration. Clinicaltrials.gov  identifier: NCT03321526."

Journal • CNS Disorders • Depression • Insomnia • Major Depressive Disorder • Mood Disorders • Psychiatry • Sleep Disorder

SEP361-304: A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. (clinicaltrials.gov) - P3 | N=305 | Completed | Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | N=475 ➔ 305

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia

SMART-BD: Sequential Multiple Assignment Randomized Trial for Bipolar Depression (clinicaltrials.gov) - P4 | N=2726 | Active, not recruiting | Sponsor: Massachusetts General Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Quetiapine Extended-Release and Peripheral Edema: A Case Report and Literature Review. (PubMed, Case Rep Psychiatry) - "While edema is more commonly associated with olanzapine and clozapine amongst second general antipsychotics, reports involving quetiapine-particularly the extended-release (XR) formulation-are rare. We describe the case of a 52-year-old woman with severe major depressive episode with psychotic features who was initiated on escitalopram and quetiapine immediate-release (IR) 100 mg/day, later switched to quetiapine XR 100 mg/day to improve adherence and reduce sedation...Literature review reveals few comparable reports, most involving higher doses or polypharmacy. This case highlights the importance of clinician awareness of quetiapine XR-associated edema, even at low doses, and supports dechallenge-rechallenge as a useful diagnostic approach to improve patient safety and adherence."

Journal • Anesthesia • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia • Thrombosis

Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release. (PubMed, Eur Psychiatry) - No abstract available

HEOR • Journal • CNS Disorders • Depression • Psychiatry

Delirious mania with catatonic features as a presenting syndrome of anti-NMDAR encephalitis: a case report (ECNP 2025) - "Despite sequential trials of olanzapine (up to 20 mg/day), quetiapine XR (up to 300 mg/day), zuclopenthixol decanoate (150 mg intramuscular every months), paliperidone (6 mg/day), and adjunctive lithium carbonate (900 mg/day, there was no clinical improvement...Rituximab was started for long-term immunomodulation, maintaining remission over one year...ConclusionA comprehensive neurodiagnostic evaluation enables early diagnosis and treatment of anti-NMDAR encephalitis. Clinicians should consider autoimmune causes in atypical neuropsychiatric cases.[5]"

Case report • Clinical • Ataxia • Bipolar Disorder • CNS Disorders • Epilepsy • Mental Retardation • Mood Disorders • Movement Disorders • Psychiatry

Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of clinical trials in adults and adolescents (ECNP 2025) - P3 | "For the trials in adults, patients aged 18–65 were randomised to placebo (total N=531), brexpiprazole (total N=1,093; 0.25, 1, 2 or 4 mg/day, or 2–4 mg/day, depending on the trial), or quetiapine extended-release (N=154; active reference in one trial). For the trial in adolescents, patients aged 13–17 were randomised to placebo (N=104), brexpiprazole 2–4 mg/day (N=110), or aripiprazole (N=102; active reference)... In this post hoc analysis of patients with early-episode schizophrenia, brexpiprazole was associated with greater improvement in schizophrenia symptoms than placebo. No new safety observations were made. Data previously presented at the 33rd European Congress of Psychiatry (EPA), 5–8 April 2025, Madrid, Spain."

Clinical • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Developments in adjunctive treatment: Seltorexant versus quetiapine in managing major depressive disorder with insomnia symptoms (ECNP 2025) - P3 | "This presentation will focus on the results from a Phase 3, 26-week, international, double-blind, active-controlled study (NCT04513912) of adjunctive seltorexant 20 mg with quetiapine-extended release (XR) as a comparator in MDD with insomnia symptoms in a subgroup of participants (18-74 years) from the European Union and United Kingdom. Y. Flossbach is a full-time employee of Actelion Pharmaceuticals Ltd., a Johnson & Johnson company, and holds stock in Johnson & Johnson"

CNS Disorders • Depression • Insomnia • Major Depressive Disorder • Mood Disorders • Psychiatry • Sleep Disorder

Phenytoin-induced manic episode in a patient with epilepsy and cerebral palsy (ECNP 2025) - "His antiepileptic regimen included levetiracetam (1000 mg/day), oxcarbazepine (600 mg/day), and lacosamide (150 mg/day)...Phenytoin was tapered off with neurology consultation, and quetiapine XR (200 mg/day) was initiated...Future research should focus on elucidating the precise mechanisms underlying these paradoxical reactions and developing clinical guidelines for safer use in high-risk populations. In the interim, clinicians should weigh the potential risks against benefits when considering phenytoin for patients with complex neurological histories and consider alternative antiepileptic options when appropriate."

Clinical • Ataxia • Bipolar Disorder • Cerebral Palsy • CNS Disorders • Epilepsy • Mood Disorders • Movement Disorders • Psychiatry • Psychomotor Agitation

An MPAN case initially presenting with psychiatric manifestations (ECNP 2025) - "At the time of admission, her medications included buspirone (15 mg/day), valproic acid (1500 mg/day), and propranolol (40 mg/day)...Intramuscular biperiden was administered, followed by oral biperiden. Olanzapine was discontinued and quetiapine XR (450 mg/day) was prescribed instead...Informed consent was obtained. No conflicts of interest were declared."

Clinical • CNS Disorders • Depression • Dystonia • Mental Retardation • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • FTL

Patient characteristics associated with relative benefit of esketamine nasal spray versus quetiapine extended release on achieving remission in ESCAPE-TRD study (ECNP 2025) - P3 | "HRs of remission in ESK-NS versus QTP-XR by baseline characteristic subgroup Baseline characteristicHR (95% CI) ESK-NS versus QTP-XRRatio of HRs (95% CI)BMI Underweight/normal Overweight/obese Missinga 1.30 (0.91, 1.84) 1.90 (1.46, 2.48) 2.56 (1.41, 4.64) Overweight/obese versus underweight/normal weight: 1.47 (0.95, 2.27)Mean age at diagnosisb1.71 (1.40, 2.09)Per 5-year increase: 0.95 (0.88, 1.04)cNumber of previous treatment failures 2 ≥3 1.54 (1.21, 1.97) 2.03 (1.45, 2.84) ≥3 versus 2 previous treatment failures: 1.32 (0.87, 2.00)Number of MDD episodes 1 >1 1.65 (1.03, 2.64) 1.73 (1.39, 2.15) 1 versus >1 episode: 0.96 (0.57, 1.61)Mean duration of episoded1.75 (1.43, 2.14)Per 10-week increase: 1.00 (0.96, 1.03) Full analysis set. [a] ≥10% patients missing data, therefore missing data category included; [b] 34.2 years; [c] Ratio of HR <1.0 indicates relative benefit of ESK-NS decreases with age; [d] 66.7 weeks."

Clinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression. (PubMed, Curr Med Res Opin) - P3 | "At 32 weeks, a significantly higher proportion of individuals in the esketamine NS group achieved remission and response compared to the quetiapine XR group (remission: 34.8% vs. 18.1%, RD [95% CI]: 16.7% [9.9%, 23.4%]; p < 0.001; response: 58.9% vs. 40.3%, RD [95% CI]:18.5% [10.9%, 26.2%]; p < 0.001). Using patient-reported PHQ-9 scoring to evaluate ESCAPE-TRD results, esketamine NS produced superior short- and long-term efficacy vs. quetiapine XR among individuals with TRD treated according to US label."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

C-SAPP: Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (clinicaltrials.gov) - P4 | N=358 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

A Review of Pharmacokinetic and Pharmacodynamic Properties of Quetiapine IR and XR: Insights and Clinical Practice Implications. (PubMed, Cureus) - "Quetiapine XR leads to a slow drug release, delays time to maximum plasma concentration (Tmax) by two to four hours, reduces peak plasma concentration (Cmax) by 13%, and lowers fluctuations in plasma concentration. These differences may have implications for careful patient selection. Long-term studies are needed for the comparison of weight gain and metabolic adverse events."

Journal • PK/PD data • Review • Anesthesia • Bipolar Disorder • CNS Disorders • Depression • Infectious Disease • Mental Retardation • Psychiatry

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression. (PubMed, J Comp Eff Res) - "Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Under the scenario analysis, the cost-per-remitter for ESK NS + OAD compared with QTP XR + OAD was $15,133.66 lower in the commercial setting and $12,487.62 lower in the Medicaid setting. The findings suggest that ESK NS + OAD is a cost-effective treatment for adults with TRD compared with QTP XR + OAD in the commercial and Medicaid settings."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Adverse events associated with four atypical antipsychotics used as augmentation treatment for major depressive disorder: A pharmacovigilance study based on the FAERS database. (PubMed, J Affect Disord) - "It is suggesting a potential increased risk of various ADEs in patients with MDD when taking AAPs. The causal relationship and the exact mechanism between drugs and ADEs remains unclear, requiring further research."

Adverse events • Journal • Cardiovascular • CNS Disorders • Depression • Glaucoma • Inflammation • Major Depressive Disorder • Mental Retardation • Metabolic Disorders • Mood Disorders • Movement Disorders • Obsessive-Compulsive Disorder • Ophthalmology • Psychiatry • Restless Legs Syndrome • Sleep Disorder